Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47.

ABSTRACT:

Background

Only a few bladder cancer patients benefit from anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy. The cluster of differentiation 47 (CD47) plays an important role in tumor immune evasion. CD47 is a highly glycosylated protein, however, the mechanisms governing CD47 glycosylation and its potential role in immunosuppression are unclear. Therefore, this study aimed to evaluate the function of CD47 glycosylation in bladder cancer.

Methods

Western blotting, immunohistochemistry, and flow cytometry were used to measure protein expression, protein-protein interactions, and phagocytosis in bladder cancer. A murine model was employed to investigate the impact of mannosidase alpha class 1B member 1 (MAN1B1) modification of CD47 on anti-phago

SUBMITTER: Zhang J 

PROVIDER: S-EPMC12479130 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature